CASE AND RESEARCH LETTER
Aprepitant in the Treatment of Refractory Pruritus Secondary to Cutaneous T-Cell Lymphoma
Tratamiento con aprepitant del prurito refractario secundario a linfoma cutáneo de células T
Leído
8649
Vecesse ha leído el artículo
2553
Total PDF
6096
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 158 | 55 | 213 |
| 2025 11 | 180 | 41 | 221 |
| 2025 10 | 157 | 42 | 199 |
| 2025 9 | 131 | 33 | 164 |
| 2025 8 | 97 | 55 | 152 |
| 2025 7 | 140 | 37 | 177 |
| 2025 6 | 134 | 44 | 178 |
| 2025 5 | 163 | 44 | 207 |
| 2025 4 | 175 | 47 | 222 |
| 2025 3 | 139 | 26 | 165 |
| 2025 2 | 149 | 30 | 179 |
| 2025 1 | 100 | 31 | 131 |
| 2024 12 | 87 | 30 | 117 |
| 2024 11 | 69 | 68 | 137 |
| 2024 10 | 77 | 52 | 129 |
| 2024 9 | 71 | 35 | 106 |
| 2024 8 | 99 | 63 | 162 |
| 2024 7 | 90 | 45 | 135 |
| 2024 6 | 114 | 41 | 155 |
| 2024 5 | 77 | 36 | 113 |
| 2024 4 | 88 | 24 | 112 |
| 2024 3 | 74 | 27 | 101 |
| 2024 2 | 63 | 40 | 103 |
| 2024 1 | 62 | 33 | 95 |
| 2023 12 | 59 | 17 | 76 |
| 2023 11 | 79 | 26 | 105 |
| 2023 10 | 65 | 23 | 88 |
| 2023 9 | 65 | 33 | 98 |
| 2023 8 | 60 | 17 | 77 |
| 2023 7 | 73 | 29 | 102 |
| 2023 6 | 63 | 23 | 86 |
| 2023 5 | 64 | 31 | 95 |
| 2023 4 | 43 | 23 | 66 |
| 2023 3 | 47 | 31 | 78 |
| 2023 2 | 49 | 19 | 68 |
| 2022 1 | 43 | 23 | 66 |
| 2022 12 | 45 | 31 | 76 |
| 2022 11 | 31 | 19 | 50 |
| 2022 10 | 34 | 25 | 59 |
| 2022 9 | 57 | 31 | 88 |
| 2022 8 | 48 | 28 | 76 |
| 2022 7 | 37 | 36 | 73 |
| 2022 6 | 28 | 28 | 56 |
| 2022 5 | 68 | 25 | 93 |
| 2022 4 | 66 | 33 | 99 |
| 2022 3 | 62 | 53 | 115 |
| 2022 2 | 49 | 18 | 67 |
| 2021 1 | 53 | 40 | 93 |
| 2021 12 | 39 | 33 | 72 |
| 2021 11 | 49 | 50 | 99 |
| 2021 10 | 39 | 40 | 79 |
| 2021 9 | 25 | 36 | 61 |
| 2021 8 | 30 | 33 | 63 |
| 2021 7 | 16 | 29 | 45 |
| 2021 6 | 33 | 26 | 59 |
| 2021 5 | 27 | 39 | 66 |
| 2021 4 | 92 | 41 | 133 |
| 2021 3 | 55 | 21 | 76 |
| 2021 2 | 68 | 22 | 90 |
| 2020 1 | 34 | 9 | 43 |
| 2020 12 | 27 | 12 | 39 |
| 2020 11 | 18 | 6 | 24 |
| 2020 10 | 20 | 7 | 27 |
| 2020 9 | 28 | 9 | 37 |
| 2020 8 | 21 | 13 | 34 |
| 2020 7 | 24 | 14 | 38 |
| 2020 6 | 28 | 15 | 43 |
| 2020 5 | 21 | 13 | 34 |
| 2020 4 | 31 | 19 | 50 |
| 2020 3 | 28 | 13 | 41 |
| 2020 2 | 4 | 0 | 4 |
| 2020 1 | 6 | 3 | 9 |
| 2019 12 | 8 | 2 | 10 |
| 2019 11 | 4 | 0 | 4 |
| 2019 10 | 2 | 2 | 4 |
| 2019 9 | 6 | 0 | 6 |
| 2019 8 | 4 | 0 | 4 |
| 2019 7 | 4 | 5 | 9 |
| 2019 6 | 4 | 7 | 11 |
| 2019 5 | 6 | 16 | 22 |
| 2019 4 | 1 | 2 | 3 |
| 2019 3 | 5 | 3 | 8 |
| 2019 1 | 5 | 0 | 5 |
| 2018 12 | 5 | 0 | 5 |
| 2018 11 | 1 | 0 | 1 |
| 2018 10 | 11 | 0 | 11 |
| 2018 9 | 4 | 0 | 4 |
| 2018 5 | 0 | 2 | 2 |
| 2018 4 | 0 | 8 | 8 |
| 2018 3 | 2 | 1 | 3 |
| 2018 2 | 23 | 7 | 30 |
| 2018 1 | 41 | 7 | 48 |
| 2017 12 | 43 | 10 | 53 |
| 2017 11 | 30 | 11 | 41 |
| 2017 10 | 38 | 6 | 44 |
| 2017 9 | 43 | 14 | 57 |
| 2017 8 | 56 | 15 | 71 |
| 2017 7 | 43 | 7 | 50 |
| 2017 6 | 55 | 17 | 72 |
| 2017 5 | 59 | 9 | 68 |
| 2017 4 | 52 | 6 | 58 |
| 2017 3 | 40 | 33 | 73 |
| 2017 2 | 33 | 9 | 42 |
| 2016 1 | 22 | 12 | 34 |
| 2016 12 | 42 | 16 | 58 |
| 2016 11 | 59 | 24 | 83 |
| 2016 10 | 53 | 18 | 71 |
| 2016 9 | 47 | 14 | 61 |
| 2016 8 | 0 | 1 | 1 |
| 2016 7 | 5 | 1 | 6 |
| 2016 6 | 8 | 7 | 15 |
| 2016 5 | 5 | 2 | 7 |
| 2016 4 | 5 | 2 | 7 |
| 2016 3 | 1 | 3 | 4 |
| 2016 2 | 6 | 2 | 8 |
| 2015 1 | 10 | 1 | 11 |
| 2015 12 | 16 | 1 | 17 |
| 2015 11 | 10 | 7 | 17 |
| 2015 10 | 8 | 8 | 16 |
| 2015 9 | 8 | 0 | 8 |
| 2015 8 | 8 | 2 | 10 |
| 2015 7 | 48 | 6 | 54 |
| 2015 6 | 53 | 7 | 60 |
| 2015 5 | 48 | 13 | 61 |
| 2015 4 | 38 | 2 | 40 |
| 2015 3 | 31 | 6 | 37 |
| 2015 2 | 46 | 5 | 51 |
| 2015 1 | 22 | 14 | 36 |
| 2014 12 | 32 | 6 | 38 |
| 2014 11 | 21 | 11 | 32 |
| 2014 10 | 47 | 12 | 59 |
| 2014 9 | 24 | 7 | 31 |
Mostrar todo
